<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03414632</url>
  </required_header>
  <id_info>
    <org_study_id>17-003021</org_study_id>
    <nct_id>NCT03414632</nct_id>
  </id_info>
  <brief_title>Transthyretin Cardiac Amyloidosis in HFpEF</brief_title>
  <official_title>Prevalence of Transthyretin Cardiac Amyloidosis in Heart Failure With Preserved Ejection Fraction: A Community Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To estimate the prevalence of transthyretin cardiac amyloidosis (TTR-CA) among Heart Failure&#xD;
      with Preserved Ejection Fraction (HFpEF) patients with increased LV wall thickness in&#xD;
      Southeast Minnesota using 99mTc-PYP single-photon positive emission computed tomography with&#xD;
      computed tomography (SPECT/CT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Residents of Southeast Minnesota over 60 years of age with an inpatient or outpatient&#xD;
      diagnosis of heart failure (HF) will be consecutively identified in real-time using a natural&#xD;
      language processing (NLP) search engine, their HF diagnosis validated, and those with a&#xD;
      recent (≤ 12 months) echocardiogram documenting a preserved EF( ≥ 40%) and LV wall thickening&#xD;
      will be consented to undergo venipuncture, urine collection and 99mTc-PYP SPECT/CT imaging to&#xD;
      rule in/out the diagnosis of TTR-CA. Hence, the prevalence of TTR-CA will be defined. To&#xD;
      place this prevalence in perspective of the global HFpEF cohort in the community, a rigorous&#xD;
      screening log will be maintained to allow generation of a comprehensive CONSORT diagram.&#xD;
      Importantly, baseline characteristics of patients who qualify for our study but decline to&#xD;
      consent will still be collected provided that consent for use of their records for medical&#xD;
      research had previously been granted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of TTR-CA</measure>
    <time_frame>Baseline</time_frame>
    <description>Determine the prevalence of Transthyretin Cardiac Amyloidosis in a community based cohort of consecutive Heart Failure with Preserved Ejection Fraction patients with increased Left Ventricular wall thickness using 99mTc-Pyrophosphate (99mTc-PYP) single-photon positive emission computed tomography with computed tomography (SPECT/CT).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">287</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>SPECT/CT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>99mTc-PYP single-photon positive emission computed tomography with computed tomography</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>99mTc-PYP</intervention_name>
    <description>Radioisotope used in the SPECT/CT imaging</description>
    <arm_group_label>SPECT/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Resident of Southeastern Minnesota (Olmsted, Dodge, Fillmore, Mower, Freeborn,&#xD;
             Wabasha, or Steele County)&#xD;
&#xD;
          2. Current diagnosis of HF per NLP search&#xD;
&#xD;
          3. Age &gt; 60 years&#xD;
&#xD;
          4. Clinically obtained echocardiogram within 12 months of index visit showing:&#xD;
&#xD;
               1. EF ≥ 40% and&#xD;
&#xD;
               2. Increased Left Ventricular (LV) wall thickness as defined by an end-diastolic&#xD;
                  left ventricular septal or posterior wall thickness (LVWTd) ≥ 20% above the upper&#xD;
                  limit of normal measured by 2D or M-mode imaging in the parasternal long (2D) or&#xD;
                  short (M-mode) axis view (≥12 mm).&#xD;
&#xD;
          5. Objective evidence of HF defined as one or more of the following present within 24&#xD;
             months of index visit:&#xD;
&#xD;
               1. Meet Framingham Criteria at index visit (In-patient or outpatient)&#xD;
&#xD;
               2. Previous HF hospitalization&#xD;
&#xD;
               3. Invasive hemodynamic documentation of elevated pulmonary capillary wedge pressure&#xD;
                  (PCWP) or left ventricular end-diastolic pressure (LVEDP) (&gt; 18 mmHg at rest or &gt;&#xD;
                  25 mmHg with exercise)&#xD;
&#xD;
               4. Left atrial enlargement + loop diuretic for HF(clinically obtained) N-terminal&#xD;
                  pro b-type natriuretic peptide (NT-proBNP) &gt; 300 (sinus rhythm) or &gt;900 (atrial&#xD;
                  fibrillation) pg/mL&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Documentation of previous EF &lt; 40%&#xD;
&#xD;
          2. Any cardiac surgery or major chest trauma within 4 weeks of index visit&#xD;
&#xD;
          3. Presence or history of hemodynamically significant left sided valvular disease defined&#xD;
             as:&#xD;
&#xD;
               1. Greater than mild mitral stenosis&#xD;
&#xD;
               2. Intrinsic mitral valve disease (prolapse, flail) with greater than moderate&#xD;
                  regurgitation&#xD;
&#xD;
          4. Myocardial infarction within 4 weeks of index visit defined by typical angina, EKG&#xD;
             changes and significant change in serial troponins. Note that chronic troponin&#xD;
             elevation is extremely common in cardiac amyloidosis. Hospitalized patients with&#xD;
             troponin elevation but no significant change (delta) on serial testing will NOT be&#xD;
             excluded.&#xD;
&#xD;
          5. Prior or current exposure to Plaquenil (Hydroxychloroquine)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omar F Abou Ezzeddine</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>January 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2018</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Omar Abou Ezzeddine</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Diastolic Heart Failure</keyword>
  <keyword>Heart Failure with Preserved Ejection Fraction</keyword>
  <keyword>Transthyretin Cardiac Amyloidosis</keyword>
  <keyword>Amyloidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

